Media
Press Release
26
2023.07
Acceptance Of Clinical Trial Application For The Recbio’s Novel Adjuvanted Recombinant Shingles Vaccine REC610 In China And Overseas Clinical Trial Progress
20
2023.03
Two-Component Recombinant COVID-19 Vaccine ReCOV Granted With Emergency Use Authorization In Mongolia
13
2023.02
Completion Of The First Batch Of Subject Enrollmentfor The Phase I Clinical Trial Of The Company’s Novel Adjuvanted Recombinant Shingles Vaccine REC610
Publications
2023.03.06
Lyophilized mRNA-lipid nanoparticle vaccines with long-term stability and high antigenicity against SARS-CoV-2
Download
2022.05.11
The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV
2022.02.12
Lyophilized mRNA-lipid nanoparticles vaccine with long-term stability and high antigenicity against SARS-CoV-2
2021.11.09
A trimeric NTD and RBD SARS-CoV-2 subunit vaccine induced protective immunity in CAG-hACE2 transgenic mice and rhesus macaques